Skip to main content
OpenTrials

Clinical trial condition

Digestive System Neoplasms

Explore clinical trials studying Digestive System Neoplasms. Study availability and eligibility vary by location and protocol.

14,203 public trials 3,225 recruiting studies
Refine in advanced search Browse all conditions

Digestive System Neoplasms trial results

Recruiting

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

NCT07671339

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Conditions
Adnexal Diseases, Advanced Malignant Neoplasm, Advanced Solid Tumor, +81 more
Locations
  • University of California Irvine Chao Family Comprehensive Cancer Center Irvine, California, United States
  • University of San Diego Moores Cancer Center La Jolla, California, United States
  • UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 77 locations
View Trial Details
Recruiting

Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

NCT07605819

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations
  • Aichi Medical University Hospital Nagakute, Aichi-ken, Japan
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Hiroshima University Hospital Hiroshima, Japan
  • JA Onomichi General Hospital Onomichi, Hiroshima, Japan
View all 48 locations
View Trial Details
Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 4905) Los Angeles, California, United States
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) East Syracuse, New York, United States
  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907) New York, United States
View all 59 locations
View Trial Details

Related conditions